BlossomHill Therapeutics reports Q2 2026 results and clinical progress

BlossomHill Therapeutics has reported its second-quarter 2026 financial results, highlighting a strengthened balance sheet following an upsized initial public offering that generated $168.3 million in gross proceeds. Combined with existing cash reserves, the company expects its resources to fund operations through the second quarter of 2028.

During the quarter, the company reported a net loss of $23.8 million, or $8.75 per share, compared to a net loss of $13.2 million in the previous year. The increased loss is attributed to higher research and development spending, which rose to $21.4 million as the company advances its oncology pipeline.

Clinical developments include encouraging early data for BH-30643, a candidate targeting advanced or metastatic EGFR C797S-positive non-small cell lung cancer. The FDA has granted Fast Track designation to BH-30643. Preliminary results from the SOLARA trial showed a 45% objective response rate and an 88% disease-control rate among patients with C797S resistance.